World Renowned Clinicians in the Fields of Cancer and Women's Health to
Assist Company in Designing its MicroRNA Development Program to Best
Address Current Medical Needs
REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, February 4 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG) announced today the establishment of its Medical Advisory Board. Rosetta Genomics has assembled world-leading clinicians in the fields of oncology and women's health, to advise the company on its microRNA-based program to develop laboratory tests to best address the issues facing oncologists and pathologists today. Some laboratory tests comprising Rosetta Genomics technology are expected to be launched in 2008.
"There is great unmet medical need for improved diagnostic and therapeutic tools within the medical community," noted Prof. Moshe Hod, Director of the Division of Maternal Fetal Medicine in the Helen Schneider Hospital for Women at Rabin Medical Center and Chairman of the Medical Advisory Board. "Rosetta Genomics has been a pioneering force in the microRNA field, and its diagnostic and therapeutic development programs may offer clinicians next-generation tools to assist patients. It is the Medical Advisory Board's responsibility to advise the company to help focus its efforts on the most significant medical needs, where microRNAs can have the most impact."
"The diagnostics field has been lagging behind therapeutics in
development, despite the tremendous importance of having objective and
accurate diagnostic tools to identify patients' conditions and manage their
therapy," noted Harvey I. Pass, M.D. Professor of Cardiothoracic Surgery
and Surgery, Director of Surgical Research, and Division Chief for Thoracic
Surgery and Thoracic Oncology for the NYU School of Medicine and Vice
Chairman of the Medical Advisory Board. "MicroRNAs have the potential to be
highly specific and sensitive biomarkers, offering clinicians th
|SOURCE Rosetta Genomics Ltd|
Copyright©2008 PR Newswire.
All rights reserved